Vertex CEO reports tax-withholding share disposition

Vertex Pharmaceuticals CEO Reshma Kewalramani reported a tax-related share transaction.

Rhea-AI Filing Summary

Vertex Pharmaceuticals CEO Reshma Kewalramani reported a tax-related share transaction. On this Form 4, she had 4,981 shares of common stock withheld at $485.11 per share to cover taxes, a type of non-market disposition. After this, she directly owned 138,278 shares of Vertex common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 4,981 shares

Exercise Price or Tax Liability 1 txn

Insider Kewalramani Reshma

Role CEO & President

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	4,981	$485.11	$2.42M

Holdings After Transaction: Common Stock — 138,278 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vertex (VRTX) CEO Reshma Kewalramani report?

Reshma Kewalramani reported a tax-related disposition of shares. 4,981 shares of Vertex common stock were withheld to satisfy tax obligations, rather than sold on the open market, and the transaction was reported on a Form 4 filing.

How many Vertex (VRTX) shares were disposed of for taxes in this Form 4?

The Form 4 shows a tax-withholding disposition of 4,981 shares of common stock. These shares were withheld to cover tax liabilities associated with equity compensation, not sold in a traditional open-market transaction or discretionary sale by the insider.

At what price were Vertex (VRTX) shares valued in the CEO’s tax-withholding transaction?

The tax-withholding disposition used a share value of $485.11 per share. This price is disclosed as the transaction price per share for the 4,981 common shares withheld to satisfy tax liabilities related to equity compensation.

How many Vertex (VRTX) shares does Reshma Kewalramani own after this Form 4 transaction?

After the tax-withholding disposition, Reshma Kewalramani directly owns 138,278 shares of Vertex common stock. This figure reflects her direct ownership following the withholding of 4,981 shares to cover associated tax obligations.

Was the Vertex (VRTX) CEO’s Form 4 transaction an open-market sale?

No, the transaction was a tax-withholding disposition, coded “F” on Form 4. Shares were withheld to pay tax liabilities on equity compensation, rather than sold as a discretionary open-market trade by the CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 06:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kewalramani Reshma

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & President

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		F		4,981	D	$485.11	138,278	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.